Table 2.
Number of isolated virus-specific T-cell populations.
| Virus | Antigen | HLA | Peptide | # of isolated T-cell populations/# of attempted isolations (%) | ||
|---|---|---|---|---|---|---|
| Per specificity | Per virus | Per HLA | ||||
| CMV | pp50 | HLA-A*01:01 | VTEHDTLLY | 7/8 (88%) |
CMV:
53/70 (76%) |
HLA-A*01:01:
29/39 (74%) |
| pp65 | HLA-A*01:01 | YSEHPTFTSQY | 6/8 (75%) | |||
| pp65 | HLA-A*02:01 | NLVPMVATV | 8/9 (89%) | |||
| IE-1 | HLA-A*02:01 | VLEETSVML | 5/9 (56%) | |||
| pp65 | HLA-B*07:02 | TPRVTGGGAM | 8/9 (89%) | |||
| pp65 | HLA-B*07:02 | RPHERNGFTVL | 8/9 (89%) |
HLA-A*02:01:
70/90 (78%) |
||
| IE-1 | HLA-B*08:01 | ELRRKMMYM | 5/9 (56%) | |||
| IE-1 | HLA-B*08:01 | QIKVRVDMV | 6/9 (67%) | |||
| EBV | LMP2 | HLA-A*01:01 | ESEERPPTPY | 4/6 (67%) |
EBV:
111/129 (86%) |
|
| LMP2 | HLA-A*02:01 | FLYALALLL | 11/12 (92%) | |||
| LMP2 | HLA-A*02:01 | CLGGLLTMV | 10/12 (83%) | |||
| EBNA3C | HLA-A*02:01 | LLDFVRFMGV | 7/12 (58%) |
HLA-B*07:02: 33/42 (79%) |
||
| BMLF1 | HLA-A*02:01 | GLCTLVAML | 10/12 (83%) | |||
| BRLF1 | HLA-A*02:01 | YVLDHLIVV | 11/12 (92%) | |||
| EBNA3A | HLA-B*07:02 | RPPIFIRRL | 11/12 (92%) | |||
| BZLF1 | HLA-B*08:01 | RAKFKQLL | 17/17 (100%) | |||
| EBNA3A | HLA-B*08:01 | FLRGRAYGL | 13/17 (76%) |
HLA-B*08:01:
58/69 (84%) |
||
| EBNA3A | HLA-B*08:01 | QAKWRLQTL | 17/17 (100%) | |||
| AdV | HEXON | HLA-A*01:01 | TDLGQNLLY | 12/17 (71%) |
AdV:
26/41 (63%) |
|
| E1A | HLA-A*02:01 | LLDQLIEEV | 8/12 (67%) | |||
| HEXON | HLA-B*07:02 | KPYSGTAYNAL | 6/12 (50%) | |||
Seventeen donors were used to isolate HLA-A*01:01/B*08:01-restricted virus-specific T cells and 12 donors were used to isolate HLA-A*02:01/B*07:02-restricted virus-specific T cells.
CMV, Cytomegalovirus; EBV, Epstein-Barr virus; AdV, Adenovirus.